Clinical trial
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With…
NCT00102739 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00102739 |
|---|---|
| Title | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) |
| Official title | See Detailed Description |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopaenic, Idiopathic |
| Intervention type | Drug |
| Interventions | SB497115 |
| Enrollment | 99 |
| Start date | Feb 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Feb 2, 2005 |
| Last update posted | Apr 15, 2013 |
| Countries | Germany, Greece, Hong Kong, New Zealand, Pakistan, Poland, Romania, Russia, Slovenia, South Korea, Taiwan, Thailand and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: